Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$8.64 – $15.00
43% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.7M | $22.5M | $21.6M | $21.9M | $20.7M | $21.2M | $33.4M | $51.3M |
| Cost of revenue | $2.3M | $2.9M | $3.1M | $3.7M | $4.0M | $4.1M | $9.3M | $17.6M |
| Gross profit | $20.4M | $19.5M | $18.6M | $18.3M | $16.7M | $17.1M | $24.1M | $33.8M |
| Gross margin | 89.8% | 87.1% | 85.9% | 83.2% | 80.7% | 80.8% | 72.2% | 65.8% |
| R&D | $561.0K | $396.0K | $129.0K | $88.0K | $98.0K | $139.0K | $0 | $21.4K |
| Operating income | $5.3M | $11.7M | $12.2M | $11.8M | $11.1M | $11.5M | $7.8M | $16.8M |
| EBITDA | $4.6M | $12.9M | $13.4M | $13.7M | $12.0M | $11.5M | $11.9M | $24.1M |
| Net income | $543.0K | $3.2M | $4.5M | $7.8M | $26.6M | $20.4M | $11.5M | $27.8M |
| Net margin | 2.4% | 14.4% | 21.1% | 35.4% | 128.8% | 96.3% | 34.6% | 54.2% |
| EPS (diluted) | 0.02 | 0.12 | 0.18 | 0.29 | 0.99 | 0.80 | 0.46 | 1.07 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $53M | $0.90 | $0.73–$1.02 | 4 |
| 2027 | $62M | $1.01 | $0.93–$1.07 | 3 |
| 2028 | $65M | $1.04 | $0.97–$1.15 | 1 |
| 2029 | $72M | $1.17 | $1.09–$1.29 | 1 |
Forward consensus · source: Financial Modeling Prep
CIPHER PHARMS INC ORD
No one on the platform currently holds CPHRF.
No tracked institution reports a position in CPHRF as of their last filing.
No one on the platform has traded CPHRF yet.
| +0.00% |
| $884 |
| — |
| HNSBFHansa Biopharma AB | $2.90 | +0.00% | $246M | — |
| MAYNFMayne Pharma Group Limited | $1.65 | +0.00% | $134M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 31.5× earnings vs its 4.9× historical median P/E.
Fair value ≈ $1.76 · price $11.39 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.